Looksmax - Men's Self Improvement Forum
Welcome to the ultimate men’s self-improvement community where like-minded individuals come together to level up every aspect of their lives. Whether it’s building confidence, improving your mindset, optimizing health, or mastering aesthetics, this is the place to become the best version of yourself. Join the hood and start your transformation today.

Water erda

(2 Viewers)
Water erda
  • Thread starter Thread starter FoidSlayer
  • Start date Start date

FoidSlayer

we will all ascend
Joined
Dec 15, 2025
Posts
9,457
Reputation
27,916
Erdafitinib is a pan fgfr inhibitor that acts on fgfrs 1-4

Erda is potent with IC50 values coming in at

1.2 nM fgfr1

2.5 nM fgfr2

3.0nM fgfr3

5.7nM fgfr4

Now let's get into it, normally in the epiphyseal plate fgfr3 is heavily expressed in the proliferation zone and once they become hypertrophic chondrocytes they predominantly express fgfr1

Fgfr3 activation → FRS2 → GRB2 → SOS → ras → raf → MEK → ERK → Brake on hypertrophic chondrocytes

Fgfr3 activation → PP2a activation → dephosphorylation of p107 → Inhibition of proliferating chondrocytes

Fgfr3 activation → STAT1 → nuclear translocation and activates cell cycle Inhibitor, p21 → inhibition of proliferating chondrocytes

Snail1 is also upregulated in the chondrocyte when fgfr3 is bound and is essential for STAT1 and MAPK signalling

Fgfr1 in the hypertrophic zone also works via similar mechanisms to inhibit how much those cells expand

fgfr2 in the growth plate helps with ossification and is located in the secondary ossification zone and also the perichondrium. Fgfr2 -/- mice had impaired PTHrP and ihh expression. This tells us that abaloparatide should be used if we inhibit fgfr2 heavily

The main fgfs that work on growth plate senescence is fgf 9 and 18

Fgfr3 Inhibition caused the physis in a patients wrist to widen, obviously because of the wider proliferation and hypertrophic zones. It also made another patients bone age stay two years behind his chronological age even post erdafitinib

The effects of erdafitinib are sex steroid independent and even with little signalling if growth factors involved (Ex. Early tanner stages ~2-3) skeletal overgrowth still occured. Probably because the growth factors that did act on his chondrocytes restored the AKT pathway but not the MAPK pathway

Normally fgfr3 downregulated AKT via GRB2 → GAB1 → PI3K → AKT downregulation

Dosing for erdafitinib for height:

Now this had me a little stumped but I figured it out, you must take clearance values, average concentration, converting ng/ml to nM, free fraction, and then running it through hills equation

Reference for 2mg erdafitinib in a healthy human

Cancer dose = 8mg

Cavg cancer patient = 1220ng/ml

Clearance cancer = 0.29

Clearance healthy = 0.43

Free fraction healthy = 0.510%

Desired dose = 2mg

Erdafitinib molecular weight = 447 g/mol

Now let's do this

Cavg healthy = 1,220 • 0.29/0.43 ≈ 823ng/ml

823 • 2/8 ≈ 206ng/ml

206/447 • 1000 = 461nM

461 • 0.00510 ≈ 2.35nM

FGFR2 = 2.35/2.35+2.5 ≈ 48% Inhibition

FGFR3 = 2.35/2.35+3.0 ≈ 43% Inhibition

Now that that's wrapped up, let's get theoretical.

Theory (grayx2 walks in)

Fgfr work in osteoblasts and suture mesenchymes in the skull. Now normally fgfr1/2/3 differentiation osteoblasts super quickly and immaturely. This causes alkaline phosphate window to decrease thus impaired hydroxyapatite.

Also immature osteoblasts release their own hydroxyapatite inhibiting signals, which is why we see a lot of fgfr deletion or activation genotypes to have poor mineralization with varying effects on bone mass and BMD

The fgfrs also inhibit bone marrow stem cells thus leaving the progenitor pool exhausted and also having less progenitors while pushing them to differentiate fast is a lot of stress

Hence why deletion genotypes still have poor mineralization, the sheer amount of progenitors just overlaps with each other and causes the system of mineralization to become sloppy.

Now Inhibition of let's say 50% of fgfr2 may help this problem and allow us to make some theoretical craniofacial gains. Now because fgfr2 is expressed in the suture mesenchymes, and taking these mesenchymal cells and differentiating them into osteoblasts super quickly via PKC→ runX2 → osteolineage

This means your sutures will differentiate slower because we are inhibiting this process. Also the more progenitors means more periosteal out growth (the fgfr deletion genotype had higher bone mass despite poorer mineralization )

Now according to implant studies, sutures experience growth after puberty, probably from strong mechanical forces. You see when a suture is histologically fused that's not the same as an implant study. A suture isn't just going to fuse one day you hit this age, it's going to gradually grow tiny bone bridges and eventually fuse completely way later in life.

And when implant studies experience the growth outside of puberty it's those little bone bridges breaking due to mechanical force but they get ossified quickly again by fgfr2

So we are essentially keeping sutures undifferentiated for longer and applying mechanical force via maxillary expansion device and orthodontic head gear to move the maxilla forward

Mechanical forces break the tiny bone bridges, so you could theoretically bonesmash whilst on erdafitinib to allow for other theoretical growth in your zygos, mandible and gonions

Then once we are done with erdafitinib, we are going to wait for the drug to leave our system once we get our head gear and expansion device unscrewed from the roof of our mouth we can then use PTHrP analog to rapidly ossify the spongy material we've created in our skull into bone

@Includings @Mr. Oxytocin fuckin fags
 

Skull

Head Moderator
Staff member
Joined
Mar 16, 2026
Posts
6,179
Reputation
27,434
good stuff

hey fuck you, rival!
 

Includings

Roided Gymcel
Joined
Apr 1, 2026
Posts
2,153
Reputation
5,031
Erdafitinib is a pan fgfr inhibitor that acts on fgfrs 1-4

Erda is potent with IC50 values coming in at

1.2 nM fgfr1

2.5 nM fgfr2

3.0nM fgfr3

5.7nM fgfr4

Now let's get into it, normally in the epiphyseal plate fgfr3 is heavily expressed in the proliferation zone and once they become hypertrophic chondrocytes they predominantly express fgfr1

Fgfr3 activation → FRS2 → GRB2 → SOS → ras → raf → MEK → ERK → Brake on hypertrophic chondrocytes

Fgfr3 activation → PP2a activation → dephosphorylation of p107 → Inhibition of proliferating chondrocytes

Fgfr3 activation → STAT1 → nuclear translocation and activates cell cycle Inhibitor, p21 → inhibition of proliferating chondrocytes

Snail1 is also upregulated in the chondrocyte when fgfr3 is bound and is essential for STAT1 and MAPK signalling

Fgfr1 in the hypertrophic zone also works via similar mechanisms to inhibit how much those cells expand

fgfr2 in the growth plate helps with ossification and is located in the secondary ossification zone and also the perichondrium. Fgfr2 -/- mice had impaired PTHrP and ihh expression. This tells us that abaloparatide should be used if we inhibit fgfr2 heavily

The main fgfs that work on growth plate senescence is fgf 9 and 18

Fgfr3 Inhibition caused the physis in a patients wrist to widen, obviously because of the wider proliferation and hypertrophic zones. It also made another patients bone age stay two years behind his chronological age even post erdafitinib

The effects of erdafitinib are sex steroid independent and even with little signalling if growth factors involved (Ex. Early tanner stages ~2-3) skeletal overgrowth still occured. Probably because the growth factors that did act on his chondrocytes restored the AKT pathway but not the MAPK pathway

Normally fgfr3 downregulated AKT via GRB2 → GAB1 → PI3K → AKT downregulation

Dosing for erdafitinib for height:

Now this had me a little stumped but I figured it out, you must take clearance values, average concentration, converting ng/ml to nM, free fraction, and then running it through hills equation

Reference for 2mg erdafitinib in a healthy human

Cancer dose = 8mg

Cavg cancer patient = 1220ng/ml

Clearance cancer = 0.29

Clearance healthy = 0.43

Free fraction healthy = 0.510%

Desired dose = 2mg

Erdafitinib molecular weight = 447 g/mol

Now let's do this

Cavg healthy = 1,220 • 0.29/0.43 ≈ 823ng/ml

823 • 2/8 ≈ 206ng/ml

206/447 • 1000 = 461nM

461 • 0.00510 ≈ 2.35nM

FGFR2 = 2.35/2.35+2.5 ≈ 48% Inhibition

FGFR3 = 2.35/2.35+3.0 ≈ 43% Inhibition

Now that that's wrapped up, let's get theoretical.

Theory (grayx2 walks in)

Fgfr work in osteoblasts and suture mesenchymes in the skull. Now normally fgfr1/2/3 differentiation osteoblasts super quickly and immaturely. This causes alkaline phosphate window to decrease thus impaired hydroxyapatite.

Also immature osteoblasts release their own hydroxyapatite inhibiting signals, which is why we see a lot of fgfr deletion or activation genotypes to have poor mineralization with varying effects on bone mass and BMD

The fgfrs also inhibit bone marrow stem cells thus leaving the progenitor pool exhausted and also having less progenitors while pushing them to differentiate fast is a lot of stress

Hence why deletion genotypes still have poor mineralization, the sheer amount of progenitors just overlaps with each other and causes the system of mineralization to become sloppy.

Now Inhibition of let's say 50% of fgfr2 may help this problem and allow us to make some theoretical craniofacial gains. Now because fgfr2 is expressed in the suture mesenchymes, and taking these mesenchymal cells and differentiating them into osteoblasts super quickly via PKC→ runX2 → osteolineage

This means your sutures will differentiate slower because we are inhibiting this process. Also the more progenitors means more periosteal out growth (the fgfr deletion genotype had higher bone mass despite poorer mineralization )

Now according to implant studies, sutures experience growth after puberty, probably from strong mechanical forces. You see when a suture is histologically fused that's not the same as an implant study. A suture isn't just going to fuse one day you hit this age, it's going to gradually grow tiny bone bridges and eventually fuse completely way later in life.

And when implant studies experience the growth outside of puberty it's those little bone bridges breaking due to mechanical force but they get ossified quickly again by fgfr2

So we are essentially keeping sutures undifferentiated for longer and applying mechanical force via maxillary expansion device and orthodontic head gear to move the maxilla forward

Mechanical forces break the tiny bone bridges, so you could theoretically bonesmash whilst on erdafitinib to allow for other theoretical growth in your zygos, mandible and gonions

Then once we are done with erdafitinib, we are going to wait for the drug to leave our system once we get our head gear and expansion device unscrewed from the roof of our mouth we can then use PTHrP analog to rapidly ossify the spongy material we've created in our skull into bone

@Includings @Mr. Oxytocin fuckin fags
Dnr, pls stop shit posting ur ruining the forum
 

Mr. Oxytocin

check it out im in the house like carpet
Joined
Mar 19, 2026
Posts
7,121
Reputation
15,728
Stolen from hypertrophy on .onl!
@Dysregulated ban now
 

Includings

Roided Gymcel
Joined
Apr 1, 2026
Posts
2,153
Reputation
5,031
They took down this other thread
Michael Jordan No GIF
 
Joined
Feb 25, 2026
Posts
3,492
Reputation
4,287
Erdafitinib is a pan fgfr inhibitor that acts on fgfrs 1-4

Erda is potent with IC50 values coming in at

1.2 nM fgfr1

2.5 nM fgfr2

3.0nM fgfr3

5.7nM fgfr4

Now let's get into it, normally in the epiphyseal plate fgfr3 is heavily expressed in the proliferation zone and once they become hypertrophic chondrocytes they predominantly express fgfr1

Fgfr3 activation → FRS2 → GRB2 → SOS → ras → raf → MEK → ERK → Brake on hypertrophic chondrocytes

Fgfr3 activation → PP2a activation → dephosphorylation of p107 → Inhibition of proliferating chondrocytes

Fgfr3 activation → STAT1 → nuclear translocation and activates cell cycle Inhibitor, p21 → inhibition of proliferating chondrocytes

Snail1 is also upregulated in the chondrocyte when fgfr3 is bound and is essential for STAT1 and MAPK signalling

Fgfr1 in the hypertrophic zone also works via similar mechanisms to inhibit how much those cells expand

fgfr2 in the growth plate helps with ossification and is located in the secondary ossification zone and also the perichondrium. Fgfr2 -/- mice had impaired PTHrP and ihh expression. This tells us that abaloparatide should be used if we inhibit fgfr2 heavily

The main fgfs that work on growth plate senescence is fgf 9 and 18

Fgfr3 Inhibition caused the physis in a patients wrist to widen, obviously because of the wider proliferation and hypertrophic zones. It also made another patients bone age stay two years behind his chronological age even post erdafitinib

The effects of erdafitinib are sex steroid independent and even with little signalling if growth factors involved (Ex. Early tanner stages ~2-3) skeletal overgrowth still occured. Probably because the growth factors that did act on his chondrocytes restored the AKT pathway but not the MAPK pathway

Normally fgfr3 downregulated AKT via GRB2 → GAB1 → PI3K → AKT downregulation

Dosing for erdafitinib for height:

Now this had me a little stumped but I figured it out, you must take clearance values, average concentration, converting ng/ml to nM, free fraction, and then running it through hills equation

Reference for 2mg erdafitinib in a healthy human

Cancer dose = 8mg

Cavg cancer patient = 1220ng/ml

Clearance cancer = 0.29

Clearance healthy = 0.43

Free fraction healthy = 0.510%

Desired dose = 2mg

Erdafitinib molecular weight = 447 g/mol

Now let's do this

Cavg healthy = 1,220 • 0.29/0.43 ≈ 823ng/ml

823 • 2/8 ≈ 206ng/ml

206/447 • 1000 = 461nM

461 • 0.00510 ≈ 2.35nM

FGFR2 = 2.35/2.35+2.5 ≈ 48% Inhibition

FGFR3 = 2.35/2.35+3.0 ≈ 43% Inhibition

Now that that's wrapped up, let's get theoretical.

Theory (grayx2 walks in)

Fgfr work in osteoblasts and suture mesenchymes in the skull. Now normally fgfr1/2/3 differentiation osteoblasts super quickly and immaturely. This causes alkaline phosphate window to decrease thus impaired hydroxyapatite.

Also immature osteoblasts release their own hydroxyapatite inhibiting signals, which is why we see a lot of fgfr deletion or activation genotypes to have poor mineralization with varying effects on bone mass and BMD

The fgfrs also inhibit bone marrow stem cells thus leaving the progenitor pool exhausted and also having less progenitors while pushing them to differentiate fast is a lot of stress

Hence why deletion genotypes still have poor mineralization, the sheer amount of progenitors just overlaps with each other and causes the system of mineralization to become sloppy.

Now Inhibition of let's say 50% of fgfr2 may help this problem and allow us to make some theoretical craniofacial gains. Now because fgfr2 is expressed in the suture mesenchymes, and taking these mesenchymal cells and differentiating them into osteoblasts super quickly via PKC→ runX2 → osteolineage

This means your sutures will differentiate slower because we are inhibiting this process. Also the more progenitors means more periosteal out growth (the fgfr deletion genotype had higher bone mass despite poorer mineralization )

Now according to implant studies, sutures experience growth after puberty, probably from strong mechanical forces. You see when a suture is histologically fused that's not the same as an implant study. A suture isn't just going to fuse one day you hit this age, it's going to gradually grow tiny bone bridges and eventually fuse completely way later in life.

And when implant studies experience the growth outside of puberty it's those little bone bridges breaking due to mechanical force but they get ossified quickly again by fgfr2

So we are essentially keeping sutures undifferentiated for longer and applying mechanical force via maxillary expansion device and orthodontic head gear to move the maxilla forward

Mechanical forces break the tiny bone bridges, so you could theoretically bonesmash whilst on erdafitinib to allow for other theoretical growth in your zygos, mandible and gonions

Then once we are done with erdafitinib, we are going to wait for the drug to leave our system once we get our head gear and expansion device unscrewed from the roof of our mouth we can then use PTHrP analog to rapidly ossify the spongy material we've created in our skull into bone

@Includings @Mr. Oxytocin fuckin fags
I fixed his IC50 values btw 😁
 

Users who are viewing this thread

Contact us

Questions about your account or the forum? Email us. To report a post, use the Report button on it.

Open email app
shape1
shape2
shape3
shape4
shape5
shape6
Back
Top
Style